Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/54016
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMark W. Tenfordeen_US
dc.contributor.authorNikhil Gupteen_US
dc.contributor.authorDavid W. Dowdyen_US
dc.contributor.authorDavid M. Asmuthen_US
dc.contributor.authorAshwin Balagopalen_US
dc.contributor.authorRichard B. Pollarden_US
dc.contributor.authorPatcharaphan Sugandhavesaen_US
dc.contributor.authorJavier R. Lamaen_US
dc.contributor.authorSandy Pillayen_US
dc.contributor.authorSandra W. Cardosoen_US
dc.contributor.authorJyoti Pawaren_US
dc.contributor.authorBreno Santosen_US
dc.contributor.authorCynthia Riviereen_US
dc.contributor.authorNoluthando Mwelaseen_US
dc.contributor.authorCecilia Kanyamaen_US
dc.contributor.authorJohnstone Kumwendaen_US
dc.contributor.authorJames G. Hakimen_US
dc.contributor.authorNagalingeswaran Kumarasamyen_US
dc.contributor.authorRobert Bollingeren_US
dc.contributor.authorRichard D. Sembaen_US
dc.contributor.authorThomas B. Campbellen_US
dc.contributor.authorAmita Guptaen_US
dc.date.accessioned2018-09-04T10:06:39Z-
dc.date.available2018-09-04T10:06:39Z-
dc.date.issued2015-02-26en_US
dc.identifier.issn19326203en_US
dc.identifier.other2-s2.0-84923869697en_US
dc.identifier.other10.1371/journal.pone.0117424en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84923869697&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/54016-
dc.description.abstract© 2015 Tenforde et al. Objective The association between pre-antiretroviral (ART) inflammation and immune activation and risk for incident tuberculosis (TB) after ART initiation among adults is uncertain. Design Nested case-control study (n = 332) within ACTG PEARLS trial of three ART regimens among 1571 HIV-infected, treatment-naïve adults in 9 countries. We compared cases (participants with incident TB diagnosed by 96 weeks) to a random sample of controls (participants who did not develop TB, stratified by country and treatment arm). Methods We measured pre-ART C-reactive protein (CRP), EndoCab IgM, ferritin, interferon gamma (IFN-γ), interleukin 6 (IL-6), interferon gamma-inducible protein 10 (IP-10), lipopolysaccharide (LPS), soluble CD14 (sCD14), tumor necrosis factor alpha (TNF-α), and CD4/DR+/38+ and CD8/DR+/38+ T cells. Markers were defined according to established cutoff definitions when available, 75thpercentile of measured values when not, and detectable versus undetectable for LPS. Using logistic regression, we measured associations between biomarkers and incident TB, adjusting for age, sex, study site, treatment arm, baseline CD4 and log10 viral load. We assessed the discriminatory value of biomarkers using receiver operating characteristic (ROC) analysis. Results Seventy-seven persons (4.9%) developed incident TB during follow-up. Elevated baseline CRP (aOR 3.25, 95% CI: 1.55-6.81) and IP-10 (aOR 1.89, 95% CI: 1.05-3.39), detectable plasma LPS (aOR 2.39, 95% CI: 1.13-5.06), and the established TB risk factors anemia and hypoalbuminemia were independently associated with incident TB. In ROC analysis, CRP, albumin, and LPS improved discrimination only modestly for TB risk when added to baseline routine patient characteristics including CD4 count, body mass index, and prior TB. Conclusion Incident TB occurs commonly after ART initiation. Although associated with higher post-ART TB risk, baseline CRP, IP-10, and LPS add limited value to routine patient characteristics in discriminating who develops active TB. Besides determining ideal cutoffs for these biomarkers, additional biomarkers should be sought that predict TB disease in ART initiators.en_US
dc.subjectAgricultural and Biological Sciencesen_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.titleC-Reactive Protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settingsen_US
dc.typeJournalen_US
article.title.sourcetitlePLoS ONEen_US
article.volume10en_US
article.stream.affiliationsJohns Hopkins Universityen_US
article.stream.affiliationsJohns Hopkins Bloomberg School of Public Healthen_US
article.stream.affiliationsUC Davis Medical Centeren_US
article.stream.affiliationsChiang Mai Universityen_US
article.stream.affiliationsAsociación Civil Impacta Salud y Educación (IMPACTA)en_US
article.stream.affiliationsThe Nelson R. Mandela Medical Schoolen_US
article.stream.affiliationsFundacao Oswaldo Cruzen_US
article.stream.affiliationsNational AIDS Research Institute Indiaen_US
article.stream.affiliationsHospital Nossa Senhora da Conceicaoen_US
article.stream.affiliationsLes Centres Groupe Haïtien d'Etude du Sarcome de Kaposi et des Infections Opportunites (GHESKIO)en_US
article.stream.affiliationsUniversity of Witwatersranden_US
article.stream.affiliationsKamuzu Central Hospitalen_US
article.stream.affiliationsMalawi College of Medicine-Johns Hopkins University Research Projecten_US
article.stream.affiliationsUniversity of Zimbabween_US
article.stream.affiliationsYR Gaitonde Centre for AIDS Research and Educationen_US
article.stream.affiliationsUniversity of Colorado School of Medicineen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.